OptimizeRx Co. (NASDAQ:OPRX) Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 9.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 444,167 shares of the company’s stock after buying an additional 39,740 shares during the quarter. Dimensional Fund Advisors LP’s holdings in OptimizeRx were worth $2,159,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Marshall Wace LLP purchased a new position in shares of OptimizeRx during the fourth quarter valued at $653,000. Walleye Capital LLC acquired a new position in OptimizeRx during the fourth quarter worth $673,000. XTX Topco Ltd bought a new position in shares of OptimizeRx in the 4th quarter valued at approximately $178,000. Barclays PLC boosted its position in OptimizeRx by 13.5% during the fourth quarter. Barclays PLC now owns 30,574 shares of the company’s stock worth $148,000 after purchasing an additional 3,640 shares during the period. Finally, Whetstone Capital Advisors LLC acquired a new position in OptimizeRx during the fourth quarter valued at approximately $6,563,000. 76.47% of the stock is owned by institutional investors and hedge funds.

Insider Activity at OptimizeRx

In related news, Director James Paul Lang acquired 321,408 shares of the business’s stock in a transaction on Friday, March 14th. The stock was bought at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

OPRX has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price objective on shares of OptimizeRx from $8.00 to $12.50 and gave the stock a “buy” rating in a research note on Tuesday. JMP Securities boosted their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the stock a “market outperform” rating in a research report on Tuesday. Roth Capital reaffirmed a “buy” rating on shares of OptimizeRx in a research report on Tuesday. B. Riley restated a “buy” rating on shares of OptimizeRx in a research note on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $10.38.

OptimizeRx Trading Down 8.2%

Shares of OptimizeRx stock opened at $10.11 on Thursday. OptimizeRx Co. has a 52-week low of $3.78 and a 52-week high of $14.13. The firm has a market capitalization of $186.96 million, a PE ratio of -7.60 and a beta of 1.28. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23. The company’s fifty day moving average price is $8.46 and its two-hundred day moving average price is $6.40.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The business had revenue of $21.93 million for the quarter, compared to analysts’ expectations of $18.69 million. On average, analysts expect that OptimizeRx Co. will post -0.33 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.